Wentworth Kerry sold $379K of NUVB
Wentworth Kerry (CHIEF REGULATORY OFFICER) sold 63,000 shares of Nuvation Bio Inc. (NUVB) at $6.02 ($0.38M total) on 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale by a regulatory officer under a pre-arranged 10b5-1 plan; absent other company-specific catalysts, it mainly informs sentiment and positioning rather than fundamentals.
Market read
Traders may note the insider sale for sentiment/flow monitoring, but the 10b5-1 structure reduces interpretive weight.
What to watch
No context is given on total insider holdings beyond the post-transaction figure, and there is no mention of concurrent buys/sales by other insiders or any company news.
Background
The article is an SEC Form 4 insider transaction disclosure for Nuvation Bio Inc. (NUVB).
Ticker impact
NUVATION BIO insider Wentworth Kerry (Chief Regulatory Officer) sold 63,000 shares at $6.0189 on 2026-06-23 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a Form 4 open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory news.
Market effects
Minimal; this is company-specific insider activity with no sector-wide regulatory or clinical read-across provided.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations, so traders may overreact if they treat it as a signal.
Key entities
- issuerNUVATION BIO INC.
Subject of the Form 4 insider sale disclosure.
- insiderWentworth Kerry
Chief Regulatory Officer who sold 63,000 shares at $6.0189/share.
